Seminars in Hematology
Volume 43 , Pages S17-S22 , April 2006

The Need for Continuing Vigilance: Addressing the Threat for Transmission of Blood-Borne Infectious Disease

  • Samuel L. Stanley Jr

      Affiliations

    • Corresponding Author InformationAddress correspondence to Samuel L. Stanley Jr, MD, Professor, Departments of Medicine and Molecular Microbiology, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110.

References 

  1. Centers for Disease Control and Prevention (CDC) US Department of Health and Human Services . Preventing Emerging Infectious Diseases (A Strategy for the 21st Century) . Atlanta, GA: Centers for Disease Control and Prevention; 1998; October
  2. Smolinski MS , Hamburg MA , Lederberg J  National Institutes of Health . Microbial Threats to Health (Emergence, Detection, and Response) . Washington, DC: National Academies Press; 2003;
  3. Ikeda Y , Nakamura K , Miyazawa T , Tohya Y , Takahashi E , Mochizuki M . Feline host range of canine parvovirus (Recent emergence of new antigenic types in cats) . Emerg Infect Dis . 2002;8:341–346
  4. Azzi A , Morfini M , Mannucci PM . The transfusion-associated transmission of parvovirus B19 . Transfus Med Rev . 1999;13:194–204
  5. Hayakawa F , Imada K , Towatari M , Saito H . Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin . Br J Haematol . 2002;118:1187–1189
  6. Carpenter JL . Feline panleukopenia (Clinical signs and differential diagnosis) . J Am Vet Med Assoc . 1971;158:857–859
  7. Michigan Society for Medical Research (MISMR): Disease brochures. Canine Parvo Virus. Available at: http://www.mismr.org/educational/parvo.html, accessed December 2005
  8. Weimer T , Streichert S , Watson C , Gröner A . High-titer screening PCR (A successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation) . Transfusion . 2001;41:1500–1504
  9. Morfini M , Azzi A , Mannucci PM . B19 parvovirus withstands “super heating” in antihemophilic concentrates . Thromb Haemost . 1996;76:821; (letter)
  10. Croghan DL , Matchett A , Koski TA . Isolation of porcine parvovirus from commercial trypsin . Appl Microbiol . 1973;26:431–433
  11. Coumau E , Peynet J , Harzic M , Beal G , Castaigne S , Leverger G , et al.   Severe parvovirus B19 infection in an immunocompetent child with hemophilia A . Arch Pediatr . 1996;3:35–39
  12. Yee TT , Cohen BJ , Pasi KJ , Lee CA . Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate . Br J Haematol . 1996;93:457–459
  13. Matsui H , Sugimoto M , Tsuji S , Shima M , Giddings J , Yoshioka A . Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate . J Pediatr Hematol Oncol . 1999;21:74–76
  14. Koenigbauer UF , Eastlund T , Day JW . Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma . Transfusion . 2000;40:1203–1206
  15. Eis-Hubinger AM , Sasowski U , Brackmann HH , Kaiser R , Matz B , Schneweis KE . Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products . Thromb Haemost . 1996;76:1120; (letter)
  16. Eis-Hubinger AM , Sasowski U , Brackmann HH . Parvovirus B19 DNA contamination in coagulation factor VIII products . Thromb Haemost . 1999;81:476–477
  17. Abe H , Sugawara H , Hirayama J , Ihara H , Kato T , Ikeda H , et al.   Removal of parvovirus B19 from hemoglobin solution by nanofiltration . Artif Cells Blood Substit Immobil Biotechnol . 2000;28:375–383
  18. Wong KT , Shieh WJ , Zaki SR , Tan CT . Nipah virus infection, an emerging paramyxoviral zoonosis . Springer Semin Immunopathol . 2002;24:215–228
  19. Chua KB , Goh KJ , Wong KT , Kamarulzaman A , Tan PS , Ksiazek TG , et al.   Fatal encephalitis due to Nipah virus among pig farmers in Malaysia . Lancet . 1999;354:1257–1259
  20. World Health Organization . Weekly Epidemiological Record . 2004;79:161–172
  21. Choi C: Nipah’s return: The lethal “flying fox” virus may spread between people. Scientific American.com [serial online]. September 13, 2004. Available at: http://www.sciam.com/article.cfm?articleID=0006321E-8ECD-111B-87CB83414B7F0000&sc=I100322, accessed December 2005
  22. Tawara A , Akahane Y , Takahashi M , Nishizawa T , Ishikawa T , Okamoto H . Transmission of human TT virus of genotype 1a to chimpanzees with fecal supernatant or serum from patients with acute TTV infection . Biochem Biophys Res Commun . 2000;278:470–476
  23. Simmonds P . TT virus infection (A novel virus-host relationship) . J Med Microbiol . 2002;51:455–458
  24. Ball JK , Curran R , Berridge S , Grabowska AM , Jameson CL , Thomson BJ , et al.   TT virus sequence heterogeneity in vivo (Evidence for co-infection with multiple genetic types) . J Gen Virol . 1999;80:1759–1768
  25. Ohto H , Ujiie N , Takeuchi C , Sato A , Hayashi A , Ishiko H , et al.   TT virus infection during childhood . Transfusion . 2002;42:892–898
  26. Knight RSG , Will RG . Prion diseases . J Neurol Neurosurg Psychiatry . 2004;75(suppl 1):i36–i42
  27. Prusiner SB . Prion diseases and the BSE crisis . Science . 1997;278:245–251
  28. Llewelyn CA , Hewitt PE , Knight RSG , Amar K , Cousens S , Mackenzie J , et al.   Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion . Lancet . 2004;363:417–421
  29. The National Creutzfeldt-Jakob Disease Surveillance Unit: CJD statistics. Available at: http://www.cjd.ed.ac.uk/figures.htm, accessed December 2005
  30. Health Protection Agency Communicable Disease Surveillance Centre . Incidence of Variant Creutzfeldt-Jakob Disease Onsets and Deaths in the UK (January 1994-December 2004) . 2005; Quarterly Report, January 19
  31. Peden AH , Head MW , Ritchie DL , Bell JE , Ironside JW . Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient . Lancet . 2004;364:527–529
  32. World Federation of Hemophilia (WFH) . TSE Task Force bulletin on vCJD risk in U.K.-sourced plasma products . 2004; September. Available at: http://www.hemophilia.ca/en/4.2.1.php, accessed December 2005
  33. World Federation of Hemophilia (WFH) . Update on vCJD and plasma products produced in France . 2004; December 14
  34. AuBuchon JP , Birkmeyer JD , Busch MP . Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood . Transfusion . 1997;37:45–51
  35. Custer B . Economic analyses of blood safety and transfusion medicine interventions (A systematic review) . Transfus Med Rev . 2004;18:127–143
  36. Aledort LM . Economic aspects of haemophilia care . Haemophilia . 1999;5:216–219
  37. Weinberg PD , Hounshell J , Sherman LA , Godwin J , Ali S , Tomori C , et al.   Legal, financial, and public health consequences of HIV contamination of blood and blood products in the 1980s and 1990s . Ann Intern Med . 2002;136:312–319

PII: S0037-1963(06)00028-X

doi: 10.1053/j.seminhematol.2006.02.004

Seminars in Hematology
Volume 43 , Pages S17-S22 , April 2006

Article Tools

* Image Usage & Resolution